LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
LTZ Therapeutics has raised $38.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2026.
LTZ Therapeutics's investors include Eli Lilly, Qiming Venture Partners, Shunwei Capital, Lanchi Ventures, 5Y Capital.
LTZ Therapeutics is headquartered in San Francisco, United States.
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
LTZ Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LTZ Therapeutics — Funding & Investors." VCBacked, May 6, 2026, https://www.vcbacked.co/company/ltz-therapeutics. Accessed September 11, 2026.
VCBacked. (2026). LTZ Therapeutics — Funding & Investors. Retrieved September 11, 2026, from https://www.vcbacked.co/company/ltz-therapeutics
{{cite web |title=LTZ Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ltz-therapeutics |website=VCBacked |access-date=September 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated